TriangleXL092 (NCT06568562)
XL092 trial for Metastatic Castration-resistant Prostate Cancer (NCT06568562). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic castration-resistant prostate adenocarcinoma that progressed during or after lutetium-177 PSMA-617. Small-cell cancer is excluded.
The idea: XL092, also called zanzalintinib, blocks kinase signals involved in tumor growth and blood-vessel formation. Patients take sixty milligrams daily in twenty-eight-day cycles. Doses may decrease for toxicity. Researchers assess whether disease remains controlled at sixteen weeks, alongside safety. Prior XL092 is excluded. Visits include examinations and tests.
This phase 2 study plans 32 patients. Umang Swami leads at Huntsman Cancer Institute, Salt Lake City, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.